Rigel Pharmaceuticals has been granted a patent for compounds of formula I-V for treating conditions involving JAK pathway modulation or JAK kinase inhibition, especially JAK3. Claim 1 specifically covers a compound of formula IV. GlobalData’s report on Rigel Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Rigel Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Rigel Pharmaceuticals's grant share as of January 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11827628B2) discloses a compound of formula IV, along with various derivatives and pharmaceutical formulations. The compound, as described in the claims, includes specific structural features such as a phenyl ring A, alkyl or substituted alkyl groups for R2, and alkyl or alkoxy groups for R3. Additionally, the patent covers methods involving the use of the compound to inhibit the activity of JAK kinase, a key enzyme involved in signaling pathways.
Furthermore, the patent outlines a method for treating allograft transplant rejection using the compound to target JAK kinase activity in transplant recipients. The method involves administering the compound in combination with other JAK kinase inhibitors to effectively treat rejection. The patent also mentions the use of the compound in pharmaceutical formulations with various excipients, diluents, and stabilizers. Overall, the patent provides a comprehensive overview of the compound's structure, derivatives, and its potential therapeutic applications in treating conditions related to JAK kinase activity.
To know more about GlobalData’s detailed insights on Rigel Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
